Notable Labs, Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kaile Zagger
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6 Jonathan Netanyahu St Or-Yehuda Israel 60376
- IPO Date
- Oct 1, 2014
- CIK
- 0001603207
- Website
- notablelabs.com
- Similar Companies
- Business
- Notable Labs, Ltd. (Nasdaq: NTBLQ) is a clinical-stage biotechnology company that develops predictive precision medicines for cancer patients through its proprietary Predictive Precision Medicines Platform (PPMP), which bio-simulates patient treatments using multi-dimensional biological assays and machine learning to predict clinical responses prior to therapy initiation; the platform enables patient selection for fast-tracked development in responsive populations, focusing on relapsed or refractory blood cancers such as acute myeloid leukemia (AML). Core offerings include the lead candidate Volasertib, a potent Polo-like kinase 1 (PLK1) inhibitor that induces cell cycle arrest and apoptosis in cancer cells; Fosciclopirox, a pro-drug of ciclopirox for AML; and additional clinical-stage candidates identified via PPMP for platform-predicted responders. The company targets oncology patients with high unmet needs, pharma partners for drug combination testing, and clinicians seeking personalized therapies; operations span the United States with headquarters in Foster City, California, following its founding in 2014. Notable Labs completed a reverse merger with VBL Therapeutics in October 2023, securing $10.3 million in private placement funding from investors including Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund to advance PPMP and Volasertib toward Phase 2a data milestones originally targeted for 2024; however, on October 13, 2024, the company filed a voluntary Chapter 7 liquidation petition in the U.S. Bankruptcy Court for the District of Delaware, resulting in delisting to OTCMKTS and leadership transition to interim CEO Kaile Zagger.
Notable Labs to Present Data on September 4th at SOHO 2024
Notable Labs Announces CEO Transition
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?
Notable Labs Reports 2023 Financial Results and Provides a Business Update
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes
Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023